Many thyroid cancer patients are exposed to long-term thyroid-stimulating hormone (TSH) suppression, often as lifetime treatment, and are consequently at risk for cardiovascular disease. We investigated the incidence of coronary heart disease (CHD) and ischemic stroke among thyroid cancer patients compared with matched control subjects.
Retrospective cohort study.
A total of 182 419 subjects who received thyroidectomy for thyroid cancer during 2004–2012 were selected from the Korean National Health Insurance data, which cover approximately 97% of the entire Korean population. Propensity score matching was used to select non-cancer controls. Cox proportional hazards regression analysis was used to determine relative risk of coronary heart disease and ischemic stroke. Mean follow-up was 4.32 years.
Thyroid cancer patients had elevated risk for CHD and ischemic stroke with hazard ratio (HR) of 1.15 (95% confidence interval (CI): 1.10–1.22) and 1.15 (1.09–1.22), respectively. This risk was increased in those who took a higher dosage of levothyroxine (HR: 1.47, 95% CI: 1.34–1.60 for CHD and HR: 1.56, 95% CI: 1.42–1.72 for ischemic stroke among those who took ≥170 μg/day levothyroxine). Although risk of atrial fibrillation was dose-dependently associated with levothyroxine dosage, it represents only a small proportion of ischemic stroke incidence (4.4%, 128/2914).
The risk for CHD and ischemic stroke was higher in thyroid cancer patients who received thyroidectomy, and the dosage of levothyroxine administered appears to play a major role. Greater caution is suggested for the screening and treatment of thyroid cancer and subsequent TSH suppression therapy, as well as proper management for cardiovascular disease prevention.
American Thyroid Association Guidelines Taskforce on Thyroid NDifferentiated Thyroid CCooperDSDohertyGMHaugenBRKloosRTLeeSLMandelSJMazzaferriELMcIverBPaciniFSchlumbergerMet al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid2009191167–1214. (https://doi.org/10.1089/thy.2009.0110)
PaciniFSchlumbergerMDralleHEliseiRSmitJWWiersingaW.European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology2006154787–803. (https://doi.org/10.1530/eje.1.02158)
SawinCTGellerAWolfPABelangerAJBakerEBacharachPWilsonPBenjaminEJD’AgostinoRB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New England Journal of Medicine19943311249–1252. (https://doi.org/10.1056/NEJM199411103311901)
DörrMEmpenKRobinsonDMWallaschofskiHFelixSBVölzkeH.The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. European Journal of Endocrinology2008159145–152. (https://doi.org/10.1530/EJE-08-0140)
AbonowaraAQuraishiASappJLAlqambarMHSaricAO’ConnellCMRajaramanMMHartRDImranSA. Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clinical and Investigative Medicine201235E152–E156. (https://doi.org/10.25011/cim.v35i3.16591)
SmitJEustatia-RuttenCCorssmitEPereiraAFrolichMBleekerGHolmanEVan Der WallERomijnJBaxJ.Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism2005906041–6047. (https://doi.org/10.1210/jc.2005-0620)
ShargorodskyMSerovSGavishDLeibovitzEHarpazDZimlichmanR.Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid200616381–386. (https://doi.org/10.1089/thy.2006.16.381)
HesselinkENKHesselinkMSKde BockGHGansevoortRTBakkerSJVredeveldEJvan der Horst-SchriversANvan der HorstICKamphuisenPWPlukkerJT.Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. Journal of Clinical Oncology2013314046–4053. (https://doi.org/10.1200/JCO.2013.49.1043)
PajamakiNMetsoSHakalaTEbelingTHuhtalaHRyodiESandJJukkola-VuorinenAKellokumpu-LehtinenPLJaatinenP.Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clinical Endocrinology201888303–310. (https://doi.org/10.1111/cen.13519)
SeongSCKimYYKhangYHHeon ParkJKangHJLeeHDoCHSongJSHyon BangJHaSet al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. International Journal of Epidemiology201646799–800. (https://doi.org/10.1093/ije/dyw253)
ShinDWSuhBLimHYunJMSongSOParkY.J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study. Journal of Bone and Mineral Research2018331037–1043. (https://doi.org/10.1002/jbmr.3407)
LeeHChoJShinDWLeeSPHwangSSOhJYangHKHwangSHSonKYChunSHet al. Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: a nationwide cohort study. Preventive Medicine20157019–25. (https://doi.org/10.1016/j.ypmed.2014.11.007)
HaugenBRAlexanderEKBibleKCDohertyGMMandelSJNikiforovYEPaciniFRandolphGWSawkaAMSchlumbergerM. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid2016261–133. (https://doi.org/10.1089/thy.2015.0020)
U. S. Preventive Services Task ForceBibbins-DomingoKGrossmanDCCurrySJBarryMJDavidsonKWDoubeniCAEplingJWJrKemperARKristAHKurthAEet al. Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement. JAMA20173171882–1887. (https://doi.org/10.1001/jama.2017.4011)
ColletTHGusseklooJBauerDCden ElzenWPCappolaARBalmerPIervasiGAsvoldBOSgarbiJAVolzkeHet al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Archives of Internal Medicine2012172799–809.
JanuaryCTCalkinsHMurrayKTCigarroaJEStevensonWG. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. Circulation20141292071–2104. (https://doi.org/10.1161/CIR.0000000000000040)
CammAJLipGYDe CaterinaRSavelievaIAtarDHohnloserSHHindricksGKirchhofPBaxJJBaumgartnerH. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. European Heart Journal2012332719–2747. (https://doi.org/10.1093/eurheartj/ehs253)
FlynnRWBonellieSRJungRTMacDonaldTMMorrisADLeeseGP.Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology and Metabolism201095186–193. (https://doi.org/10.1210/jc.2009-1625)
FommeiEIervasiG.The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. Journal of Clinical Endocrinology and Metabolism2002871996–2000. (https://doi.org/10.1210/jcem.87.5.8464)
EssermanLJThompsonIMReidBNelsonPRansohoffDFWelchHGHwangSBerryDAKinzlerKWBlackWC.Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology201415e234–e242. (https://doi.org/10.1016/S1470-2045(13)70598-9)
ParkSOhCMChoHLeeJYJungKWJunJKWonYJKongHJChoiKSLeeYJet al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ2016355i5745. (https://doi.org/10.1136/bmj.i5745)
ChoBYChoiHSParkYJLimJAAhnHYLeeEKKimKWYiKHChungJKYounYKet al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid201323797–804. (https://doi.org/10.1089/thy.2012.0329)